Table 1.
Patients’ characteristics: (A) demographic and clinical, (B) advanced anti-inflammatory treatments, (C) blood tests and vital signs.
|
A - Demographic, comorbidities and admission parameters |
N = 563 |
| Age (years), median (IQR) | 51.1 (33.4–66.26) |
| Male | 46% |
| Department of hospitalization | |
| Internal medicine wing | 60.9% |
| Dermatology | 11.0% |
| Surgery wing | 20.1% |
| Orthopedics | 3.0% |
| Gynecology | 3.9% |
| Intensive care | 1.1% |
| Reason for hospitalization | |
| Infectious | 23.6% |
| Non infectious | 76.4% |
| Comorbidities* | |
| IHD | 2.3% |
| CVD | 4.2% |
| CHF | 3.6% |
| DM | 12.3% |
| COPD | 11.0% |
| PVD | 1.9% |
| Renal disease | 6.1% |
| Dementia | 0.0% |
| Liver disease | 3.9% |
| Tumor | 5.8% |
| Lymphoma | 1.3% |
| Peptic ulcer | 1.6% |
| AIDS | 0.3% |
| *Noted in 303 patients in whom Charslon score was available in the data search results | |
|
B - Chronic advanced anti-inflammatory treatment | |
| Tocilizumab | 2.5% |
| Anti-TNF | |
| Infliximab | 23.1% |
| Adalimumab | 43.2% |
| Etanercept | 14.9% |
| Certolizumab | 1.6% |
| Golimumab | 2.8% |
| JAK-inhibitor | |
| Tofacitinib | 3.7% |
| Baricitinib | 0.2% |
| Others | |
| Rituximab | 4.3% |
| Abatacept | 2.3% |
| Anakinra |
1.4% |
|
C - Blood tests and vital signs | |
| Blood tests | |
| CRP (mg/dL), median (IQR) | 24.7 (6.5–93.6) |
| WBC (K/μL), median (IQR), | 8.6 (6.3–11.1) |
| Neutrophils (K/μL), median (IQR) | 5.6 (3.8–8.3) |
| PLT (K/μL), median (IQR) | 236 (180–306) |
| Albumin (g/L), mean (SD) | 36.7 (5.8) |
| Creatinine (mg/dL), median (IQR) | 0.80 (0.65–0.99) |
| Vital signs | |
| Heart rate (bpm), mean (SD) | 81 (16.03) |
| SBP (mmHg), mean (SD) | 127 (21.56) |
| DBP (mmHg), mean (SD) | 73 (19.92) |
| Temperature (C०), mean (SD) | 36.8 (0.47) |
IHD - Ischemic heart disease; CVD - Cardiovascular diseases; CHF - Congestive heart failure; DM - Diabetes mellitus; COPD - Chronic obstructive pulmonary disease; PVD - Peripheral Vascular Disease; AIDS - Acquired immunodeficiency syndrome; TNF - Tumor necrosis factor; JAK - Janus kinase inhibitors; CRP - C-reactive protein; WBC - White blood cells; PLT - Platelets; SBP - Systolic blood pressure; DBP - Diastolic blood pressure.